Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma

Fujimoto,Nobukazu; Gemba,Kenichi; Asano,Michiko; Wada,Sae; Ono,Katsuichiro; Ozaki,Shinji; Kishimoto,Takumi

doi:10.3892/etm_00000048

Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma

Authors:
- Nobukazu Fujimoto
- Kenichi Gemba
- Michiko Asano
- Sae Wada
- Katsuichiro Ono
- Shinji Ozaki
- Takumi Kishimoto
View Affiliations

Affiliations: Department of Respiratory Medicine, Okayama Rosai Hospital, Okayama 7028055, Japan
Published online on: March 1, 2010 https://doi.org/10.3892/etm_00000048
Pages: 313-317

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm primarily arising from surface serosal cells of the pleura and is strongly associated with asbestos exposure. Patients with MPM often develop pleural fluid as initial presentation. However, cytological diagnosis using pleural fluid is usually difficult and has limited utility. A useful molecular marker for differential diagnosis particularly with lung cancer (LC) is urgently needed. The aim of the present study was to investigate the diagnostic value of soluble mesothelin-related protein (SMRP) in pleural fluid. Pleural fluids were collected from 23 patients with MPM, 38 with LC, 26 with benign asbestos pleurisy (BAP), 5 with tuberculosis pleurisy (TP) and 4 with chronic heart failure (CHF), and the SMRP concentration was determined. All data were analyzed by using non-parametric two-sided statistical tests. The median concentration of SMRP in MPM, LC, BAP, TP and CHF were 11.5 (range 0.90-82.80), 5.20 (0.05-36.40), 6.65 (1.45-11.25), 3.20 (1.65-6.50) and 2.03 (1.35-2.80) nmol/l, respectively. The SMRP concentration was significantly higher in MPM than in the other diseases (P=0.001). The area under the ROC curve (AUC) values of the MPM diagnosis was 0.75 for the differential diagnosis from the other groups. Based on the cut-off value of 8 nmol/l, the sensitivity and specificity for diagnosis of MPM were 70.0 and 68.4%, respectively. These results indicate that the SMRP concentration in pleural fluid is a useful marker for the diagnosis of MPM.

View Figures

View References

1.	Ohshima H: Five cases with mesothelioma living near a now-defunct asbestos cement plant in Amagasaki city. Mainichi Newspaper (in Japanese). 1June 29–2005.
2.	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Ray M and Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 136:888–896. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Shi HZ, Liang QL, Jiang J, Qin XJ and Yang HB: Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 13:518–527. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J and Yang HB: Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 63:35–41. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Aoe K, Hiraki A, Maeda T, et al: Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion. Chest. 126:1195–1197. 2004. View Article : Google Scholar
7.	Rump A, Morikawa Y, Tanaka M, et al: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 279:9190–9198. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Chang K, Pai LH, Pass H, et al: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 16:259–268. 1992. View Article : Google Scholar : PubMed/NCBI
9.	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
10.	Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 16:192–197. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Ordonez NG: The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 27:1031–1051. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Scholler N, Fu N, Yang Y, et al: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA. 96:11531–11536. 1999. View Article : Google Scholar
13.	Frierson HF Jr, Moskaluk CA, Powell SM, et al: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 34:605–609. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Hornick JL, Lauwers GY and Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 29:381–389. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Watanabe H, Okada G, Ohtsubo K, et al: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas and chronic pancreatitis. Pancreas. 30:349–354. 2005. View Article : Google Scholar
17.	Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 10:3937–3942. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Robinson BW, Creaney J, Lake R, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 362:1612–1616. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Cristaudo A, Foddis R, Vivaldi A, et al: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 13:5076–5081. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M and Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 3:1317–1324. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Scherpereel A, Grigoriu B, Conti M, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 173:1155–1160. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Pass HI, Wali A, Tang N, et al: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 85:265–272. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 14:1–12. 1996. View Article : Google Scholar
24.	Histological Typing of Lung and Pleural Tumors. World Health Organization; Geneva: 1999
25.	Mountain CF: Revisions in the International System for staging lung cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Kohyama N and Suzuki Y: Analysis of asbestos fibers in lung parenchyma, pleural plaques and mesothelioma tissues of North American insulation workers. Ann NY Acad Sci. 643:27–52. 1991. View Article : Google Scholar : PubMed/NCBI
27.	Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 170:691–715. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Raviglione MC and Luelmo F: Update on the global epidemiology of tuberculosis. Curr Issues Public Health. 2:192–197. 1996.PubMed/NCBI
29.	Hiraki A, Aoe K, Eda R, et al: Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 125:987–989. 2004. View Article : Google Scholar : PubMed/NCBI